Latest "Identification potassium phosphite responsive miRNAs their targets potato" News Stories

22:56 EST 19th November 2019 | BioPortfolio

Here are the most relevant search results for "Identification potassium phosphite responsive miRNAs their targets potato" found in our extensive news archives from over 250 global news sources.

More Information about Identification potassium phosphite responsive miRNAs their targets potato on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Identification potassium phosphite responsive miRNAs their targets potato for you to read. Along with our medical data and news we also list Identification potassium phosphite responsive miRNAs their targets potato Clinical Trials, which are updated daily. BioPortfolio also has a large database of Identification potassium phosphite responsive miRNAs their targets potato Companies for you to search.

Showing "Identification potassium phosphite responsive miRNAs their targets potato" News Articles 1–25 of 3,600+

Tuesday 19th November 2019

Lucence Raises USD $20M Series A Led by IHH Healthcare to Advance Liquid Biopsy for Early Detection of Multiple Cancers

Lucence, a genomic medicine company that invents blood-based tests for cancer screening and treatment selection, announced today the close of USD $20 million in Series A funding. The round was led by IHH Healthcare, one of the world’s largest integrated private healthcare groups. SGInnovate, together with existing investors Temasek Holdings subsidiary Heliconia Capital, Lim Kaling, Koh Boon Hwe...

Conversational AI leader announces OrbitaASSIST, a digitally reimagined voice-powered, AI-driven virtual health assistant proven to improve patient communication at the bedside

Research shows as much as 70% reduction in median response time to calls for help, 87% of nurses feeling more confident in responding to calls, and 100% of patients preferring it for future hospitalization BOSTON and SYDNEY, Nov. 19, 2019 /PRNewswire/ -- Orbita, the provider of healthcare's most powerful conversational AI platform, announced today that i...

Firmenich Proves Malodor Control Is a Key Lever in Tackling Today's Sanitation Crisis

GENEVA, Nov. 19, 2019 /PRNewswire/ -- Marking World Toilet Day, Firmenich, the world's largest privately-owned perfume and taste company, released pioneering research demonstrating that malodor control is a key lever in tackling today's sanitation crisis. The four-country study, released at the Global Sanitation Economy Summit 2019 in Pune, India, found that effect...

US Humane Cosmetics Act Backed By Industry And NGOs Alike; Here’s Why

The proposed bill in the US Senate could be seen as slightly friendlier to the cosmetics industry when it comes...    

Identification of a radical SAM enzyme involved in the synthesis of archaeosine

Identification and functional validation of genetic variants in potential miRNA target sites of established BMI genes

Solar Stock News: SinglePoint (OTCQB: $SING) Subsidiary Direct Solar Making Major Headway as Expansion Continues

PHOENIX - November 19, 2019 ( Newswire) Direct Solar a subsidiary of SinglePoint Inc. (OTCQB:SING), a leading residential and commercial solar brokerage, continues to exceed revenue growth targets and has been pivotal to improving the Company's financials.

Biolog-id Raises 30 Million Euros From Funds Managed by Xerys

Biolog-id, a global leader in the traceability and management of sensitive health products (red blood cells, plasma, platelets and chemotherapy preparations), is announcing a campaign to raise 30 million euros from Xerys Funds. This press release features multimedia. View the full release here: With this campaign, Biolog-id aims to exceed...

Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies

Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to investigate novel biomarkers of response and mechanisms of resistance to cancer therapies. Merck KGaA, Darmstadt, Germany, will utilize Personalis’ newest cancer immunogenomics platform, ImmunoID NeXT™, for ...

Arrakis Therapeutics Appoints Elizabeth Radcliffe as Vice President of Finance and Strategy

Biotech business leader brings extensive financial and strategic planning experience across many stages of product development and company growth Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA, today announced that Elizabeth Radcliffe has joined as the company’s Vice President of Finance

The Healthcare World According To Andrew Witty

The former GlaxoSmithKline CEO has given his views on the prospects for healthcare systems, saying that intelligently applying digital technologies...  &#

Syros to Present on Core Drivers of Metastasis in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the company and its collaborators from the Whitehead Institute for Biomedical Research will present on the identification of core drivers of metastasis in triple-negative breast cancer (TNBC) in a poster presentation at the 2019 San Antonio Breast Cancer Symposi...

Amneal Starts Seeking International Partners

In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing...   

Mitre Medical Receives FDA Approval For the ENRAPT-US Early Feasibility Study

The Mitral Touch Empowers Surgeons to Treat Functional MR on a Beating Heart MORGAN HILL, Calif. (PRWEB) November 19, 2019 Mitre Medical is pleased to announce concurrent to the PCR-London Valves Conference that the FDA has determined Mitre Medical Corp. has provided sufficient data to support initiation of a human clinical study to evaluate the safety and performance of the Mitral Touch System t...

Novo Nordisk, Dicerna enter R&D deal for liver-focused drug targets

Novo Nordisk has entered a research and development deal with Dicerna Pharmaceuticals that will analyze over 30 liver cell  -More- 

Monday 18th November 2019

Researchers develop a database to aid in identifying key genes for bacterial infections

(Universitat Autonoma de Barcelona) A team of scientists from the Universitat Autonoma de Barcelona and the Centre de Regulació Genomica have created the BacFITBase database, which characterises bacterial genes relevant to the infection process in live organisms. The new database will make it easier to identify new therapeutic targets for the creation of antibiotics.

Codiak Presents First Preclinical Data for exoASO, Engineered Exosomes Designed to Reprogram Tumor-Associated Macrophages

- Engineered exosomes incorporating an antisense oligonucleotide induced potent, single-agent anti-tumor activity - - Represents a first-in-class, highly selective strategy to target and reprogram tumor-associated macrophages - Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced the first preclinical data...

Celsius Targets Nordic And Wider European Growth On Func Food Purchase

Celsius Holdings acquires Nordic wellness company Func Foods Oyj, expanding its portfolio with four Nordic-distributed brands and gaining a platform...   

Prevagen Among Magazine's Top 'Brain' Supplements; FTC Complaint Ongoing

Prevagen among four products named “Best of Supplements” for "brain health" by Better Nutrition Magazine. FTC proceeds with complaint against...   

Dicerna and Novo Nordisk Partner for Discovery and Development of RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

LEXINGTON, Mass., & BAGSVÆRD, Denmark–(BUSINESS WIRE)–Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) and Novo Nordisk A/S today announced an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration plans to explore more than 30 liver cell tar...

Bayer and Dewpoint create deal around biomolecular condensates in cardiovascular and gynecological diseases

Bayer AG received an option to license a certain number of small molecules generated against Dewpoint Therapeutics’ biomole...

Sarepta, Stride co-develop AAV gene therapies for up to eight CNS/neuromuscular targets

Sarepta Therapeutics Inc. and StrideBio Inc. agreed to collaborate on the development of in vivo adeno-associated viral (AAV)...

Mannatech Declares Third Quarter 2019 Dividend

Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, announced that its Board of Directors declared a cash dividend of $0.125 per share of common stock, payable on Friday, December 27, 2019, to shareholders of record at the close of business on Friday, December 13, 2019. The dividend reflects a commitment to rewarding...

Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure

The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.    

What Is the Optimal Cholesterol Level After Stroke or TIA?

A randomized trial of two LDL targets suggests that the lower target is better.

Quick Search

News Quicklinks